Switch theme
Sign up to access all valuation multiples
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
2000
341
LTM Revenue $125M
LTM EBITDA n/a
-$84.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Macrogenics has a last 12-month revenue of $125M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Macrogenics achieved revenue of $148M and an EBITDA of -$57.4M.
Macrogenics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Macrogenics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $57.2M | $148M | XXX | XXX | XXX |
| Gross Profit | $143M | $49.0M | XXX | XXX | XXX |
| Gross Margin | 249% | 33% | XXX | XXX | XXX |
| EBITDA | $2.0M | -$57.4M | XXX | XXX | XXX |
| EBITDA Margin | 4% | -39% | XXX | XXX | XXX |
| Net Profit | -$120M | -$9.1M | XXX | XXX | XXX |
| Net Margin | -209% | -6% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Macrogenics's stock price is $1.
Macrogenics has current market cap of $80.1M, and EV of -$84.1M.
See Macrogenics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$84.1M | $80.1M | XXX | XXX | XXX | XXX | $-1.50 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Macrogenics has market cap of $80.1M and EV of -$84.1M.
Macrogenics's trades at -0.7x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Macrogenics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Macrogenics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$84.1M | XXX | XXX | XXX |
| EV/Revenue | -0.6x | XXX | XXX | XXX |
| EV/EBITDA | 1.5x | XXX | XXX | XXX |
| P/E | -1.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 1.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMacrogenics's NTM/LTM revenue growth is -45%
Macrogenics's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.7M for the same period.
Over next 12 months, Macrogenics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Macrogenics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Macrogenics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 159% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -39% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -2944% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -83% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.7M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 119% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 166% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Macrogenics acquired XXX companies to date.
Last acquisition by Macrogenics was XXXXXXXX, XXXXX XXXXX XXXXXX . Macrogenics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Macrogenics founded? | Macrogenics was founded in 2000. |
| Where is Macrogenics headquartered? | Macrogenics is headquartered in United States of America. |
| How many employees does Macrogenics have? | As of today, Macrogenics has 341 employees. |
| Who is the CEO of Macrogenics? | Macrogenics's CEO is Dr. Scott Koenig, M.D.,PhD. |
| Is Macrogenics publicy listed? | Yes, Macrogenics is a public company listed on NAS. |
| What is the stock symbol of Macrogenics? | Macrogenics trades under MGNX ticker. |
| When did Macrogenics go public? | Macrogenics went public in 2013. |
| Who are competitors of Macrogenics? | Similar companies to Macrogenics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Macrogenics? | Macrogenics's current market cap is $80.1M |
| What is the current revenue of Macrogenics? | Macrogenics's last 12-month revenue is $125M. |
| What is the current EV/Revenue multiple of Macrogenics? | Current revenue multiple of Macrogenics is -0.7x. |
| What is the current revenue growth of Macrogenics? | Macrogenics revenue growth between 2023 and 2024 was 159%. |
| Is Macrogenics profitable? | Yes, Macrogenics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
